- Home
- CLM vs SWTX Comparison
CLM vs SWTX Comparison
Compare CLM & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- SWTX
- Stock Information
- Founded
- CLM 1987
- SWTX 2017
- Country
- CLM United States
- SWTX United States
- Employees
- CLM N/A
- SWTX N/A
- Industry
- CLM Finance/Investors Services
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLM Finance
- SWTX Health Care
- Exchange
- CLM Nasdaq
- SWTX Nasdaq
- Market Cap
- CLM 2.1B
- SWTX 2.2B
- IPO Year
- CLM N/A
- SWTX 2019
- Fundamental
- Price
- CLM $8.43
- SWTX $35.59
- Analyst Decision
- CLM
- SWTX Strong Buy
- Analyst Count
- CLM 0
- SWTX 5
- Target Price
- CLM N/A
- SWTX $67.00
- AVG Volume (30 Days)
- CLM 1.4M
- SWTX 1.1M
- Earning Date
- CLM 01-01-0001
- SWTX 11-12-2024
- Dividend Yield
- CLM 18.74%
- SWTX N/A
- EPS Growth
- CLM N/A
- SWTX N/A
- EPS
- CLM N/A
- SWTX N/A
- Revenue
- CLM N/A
- SWTX $135,487,000.00
- Revenue This Year
- CLM N/A
- SWTX $3,426.90
- Revenue Next Year
- CLM N/A
- SWTX $88.92
- P/E Ratio
- CLM N/A
- SWTX N/A
- Revenue Growth
- CLM N/A
- SWTX N/A
- 52 Week Low
- CLM $6.25
- SWTX $28.21
- 52 Week High
- CLM $8.84
- SWTX $53.92
- Technical
- Relative Strength Index (RSI)
- CLM 45.19
- SWTX 39.83
- Support Level
- CLM $8.16
- SWTX $34.36
- Resistance Level
- CLM $8.80
- SWTX $42.51
- Average True Range (ATR)
- CLM 0.25
- SWTX 1.80
- MACD
- CLM -0.09
- SWTX -0.97
- Stochastic Oscillator
- CLM 35.52
- SWTX 11.69
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.